Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study

Abstract Objective To investigate the long-term efficacy and safety of the IL-6 receptor antibody tocilizumab in patients with Takayasu arteritis (TAK). Methods Patients completing the randomized, double-blind, placebo-controlled period of the TAKT (Takayasu arteritis Treated with Tocilizumab) trial...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Rheumatology (Oxford, England) England), 2020-09, Vol.59 (9), p.2427-2434
Hauptverfasser:	Nakaoka, Yoshikazu, Isobe, Mitsuaki, Tanaka, Yoshiya, Ishii, Tomonori, Ooka, Seido, Niiro, Hiroaki, Tamura, Naoto, Banno, Shogo, Yoshifuji, Hajime, Sakata, Yasushi, Kawakami, Atsushi, Atsumi, Tatsuya, Furuta, Shunsuke, Kohsaka, Hitoshi, Suzuki, Katsuya, Hara, Ryoki, Maejima, Yasuhiro, Tsukamoto, Hiroshi, Takasaki, Yoshinari, Yamashita, Katsuhisa, Okada, Norihiro, Yamakido, Shinji, Takei, Syuji, Yokota, Shumpei, Nishimoto, Norihiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal, Humanized - administration & dosage Clinical Science Double-Blind Method Drug Therapy, Combination Female Glucocorticoids - administration & dosage Humans Induction Chemotherapy Male Recurrence Takayasu Arteritis - drug therapy Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!